Streetbeat News

MEDP

Medpace Holdings, Inc.

https://www.medpace.com

Industry

Medical - Diagnostics & Research

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

Open

308.42

Mkt cap

9.8B

Volume

217K

High

317.64

P/E Ratio

27.72

52-wk high

459.77

Low

305.88

Div yield

N/A

52-wk low

268.80

Medpace Holdings reported Q3 2024 earnings per share of $3.01, surpassing the expected $2.78, but sales of $533.3 million fell short of the $540.987 million estimate. Despite the sales miss, revenue increased by 8.28% compared to the previous year.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 8:16 pm

Medpace Hldgs (NASDAQ:MEDP) is set to announce its quarterly earnings on October 21, 2024, with analysts estimating an EPS of $2.80. The market is optimistic about the company surpassing estimates and providing positive guidance. Historically, Medpace's earnings announcements have led to significant stock price movements. Analysts have given Medpace a Neutral rating with a one-year price target of $395.6, indicating a potential 15.37% upside. Medpace shows strong financial performance with high revenue growth and profitability compared to peers.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 6:22 pm

Medpace Hldgs (NASDAQ:MEDP) is set to release its quarterly earnings report on October 21, 2024, with analysts expecting an EPS of $2.80. Despite a previous EPS beat, the stock dropped 18.27% last quarter. Analysts have a Neutral consensus with a price target of $395.6, indicating a potential 15.37% upside. Medpace shows strong profitability and growth compared to peers.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 6:20 pm

Medpace Hldgs (NASDAQ:MEDP) is set to release its quarterly earnings on October 21, 2024, with analysts expecting an EPS of $2.80. Despite a past trend of share price drops post-earnings, the stock has seen a 55.52% increase over the last year. Analysts rate the stock as Neutral with a price target suggesting a 15.37% upside.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 6:18 pm

Medpace Hldgs (NASDAQ:MEDP) is set to announce its quarterly earnings on October 21, 2024, with analysts estimating an EPS of $2.80. Despite a previous EPS beat, the stock saw a significant drop, highlighting the importance of guidance in market reactions. The company's shares have risen 55.27% over the past year, and analysts have a Neutral rating with a price target suggesting a 15.37% upside. Medpace shows strong revenue growth and profitability compared to peers, but has room for improvement in return on equity.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 6:16 pm

Medpace Hldgs (NASDAQ:MEDP) is set to release its quarterly earnings on October 21, 2024. Analysts expect an EPS of $2.80. Despite past EPS beats, the stock has shown volatile reactions, with a significant drop after the last earnings report. The stock is up 53.36% over the past year, and analysts have a Neutral consensus with a price target suggesting a 15.37% upside. Medpace shows strong financial metrics compared to peers, with high revenue growth, net margin, and return on equity.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 2:02 pm

Redburn Atlantic has initiated coverage on Medpace Holdings with a Buy rating and set a price target of $404.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 4:08 pm

Medpace Holdings (NASDAQ:MEDP) has seen a shift in analyst sentiment, with recent evaluations showing a decrease in average price targets by 8.75%. Analysts have adjusted their ratings, with several lowering their price targets. Despite this, Medpace has demonstrated strong financial performance, with impressive revenue growth, net margin, and return on equity.

Portfolio Pulse from Benzinga Insights

October 14, 2024 | 3:00 pm

Truist Securities has maintained a Hold rating on Medpace Holdings (NASDAQ:MEDP) while lowering the price target from $415 to $397.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 2:17 pm

Medpace Holdings (NYSE:MEDP) has seen a 7.88% increase in short interest, with 933,000 shares sold short, representing 4.52% of its float. This is below the peer group average of 5.44%. Short interest can indicate market sentiment, with rising short interest suggesting bearish sentiment.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 3:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.